Supernus Pharmaceuticals, Inc. $SUPN is Ashford Capital Management Inc.’s 4th Largest Position

Ashford Capital Management Inc. increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 645,381 shares of the specialty pharmaceutical company’s stock after purchasing an additional 32,843 shares during the period. Supernus Pharmaceuticals accounts for about 4.1% of Ashford Capital Management Inc.’s investment portfolio, making the stock its 4th biggest holding. Ashford Capital Management Inc.’s holdings in Supernus Pharmaceuticals were worth $33,360,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in SUPN. State Street Corp boosted its position in Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after buying an additional 31,668 shares during the period. Geode Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after acquiring an additional 62,875 shares during the period. Loomis Sayles & Co. L P raised its stake in shares of Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after acquiring an additional 162,905 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after acquiring an additional 61,120 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares during the period.

Wall Street Analyst Weigh In

Several research analysts recently commented on SUPN shares. Wall Street Zen cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $62.83.

Supernus Pharmaceuticals Trading Up 1.7%

Shares of SUPN stock opened at $46.98 on Tuesday. The firm has a fifty day moving average price of $46.46 and a 200 day moving average price of $49.23. The company has a market cap of $2.73 billion, a P/E ratio of -92.12, a PEG ratio of 0.99 and a beta of 0.54. Supernus Pharmaceuticals, Inc. has a 12 month low of $32.83 and a 12 month high of $59.68.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.